Abnormal Liver Tests during Hospitalization Predict Mortality in Patients with COVID-19: A Multicenter Study from South America

Table 2

Clinical course of patients hospitalized for COVID-19.

Variable	No ALEx2 (n = 211)	ALEx2 (n = 87)	value
Transfer to ICU, n (%)	99 (47.1)	38 (43.7)	0.59
Vasopressors use, n (%)	45 (21.8)	20 (23.3)	0.8
Need for mechanical ventilation, n (%)	72 (34.1)	27 (31)	0.61
Length of mechanical ventilation (days), median (IQR)	15 (8–24.8)	13 (7.5–16.5)	0.11
Length of ICU admission (days), median (IQR)	13 (6–23.5)	12 (5–16.8)	0.13
Length of hospitalization (days), median (IQR)	14 (7–23.5)	11 (7–20)	0.055
Mortality
Days 0–7, n (%)	6 (2.8)	8 (9.2)	0.031
Days 8–14, n (%)	9 (4.4)	4 (5.1)	0.85
Days 15–21, n (%)	16 (8.2)	7 (9.4)	0.91
Days 22–28, n (%)	2 (1.1)	1 (1.5)	0.63
Days 29–60, n (%)	12 (6.7)	1 (1.5)	0.15
Overall, n (%)	45 (21.5)	21 (24.1)	0.62

ALEx2, abnormal liver enzymes >2 times over the upper limit of normal; ICU, intensive care unit; IQR, interquartile range.